Vibha Sharma
Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.
Latest From Vibha Sharma
WHO ‘Showed Leadership’ In Dealing With COVID-19, Says Interim Inquiry
An interim independent assessment of the WHO’s response to the COVID-19 pandemic has supported the organization’s work. But will be it enough to convince critics as the WHO faces the threat of permanently losing funds from its biggest donor, the US?
WHO ‘Showed Leadership’ In Dealing With COVID-19, Says Interim Inquiry
An interim independent assessment of the WHO’s response to the COVID-19 pandemic has supported the organization’s work. But will be it enough to convince critics as the WHO faces the threat of permanently losing funds from its biggest donor, the US?
Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.
Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.
EU Regulators Concerned By Mushrooming Of Small COVID-19 Trials
Based on experience from earlier epidemics, EU regulators are concerned that the high number of COVID-19 trials starting in a confined geography at the peak of the coronavirus pandemic will not be able to enrol patients up to their pre-established sample size.
EMA Strengthens Breast Cancer Risk Info For Menopause HRT Medicines
An EU panel has suggested changing the safety information for hormone replacement therapy medicines for menopause to clarify that breast cancer risk can persist in women even after stopping HRT.